UroGen Pharma Ltd. (URGN)
NASDAQ·Healthcare·Biotechnology
$24.15
+1.58%
Mkt Cap $1.18B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 2, 2026 | $39.91M | $37.84M | -5.20% | -$0.52 | -$0.54 | -4.25% | — | — |
| Q4 2025 Nov 6, 2025 | $40.13M | $27.48M | -31.53% | -$0.72 | -$0.69 | +4.17% | — | — |
| Q3 2025 Aug 7, 2025 | $33.57M | $24.21M | -27.87% | -$0.82 | -$1.05 | -28.05% | — | — |
| Q2 2025 May 12, 2025 | $23.26M | $20.25M | -12.93% | -$0.83 | -$0.92 | -10.84% | — | — |
| Q1 2025 Mar 10, 2025 | $23.34M | $24.57M | +5.24% | -$0.69 | -$0.80 | -15.94% | — | — |
| Q4 2024 Nov 6, 2024 | $26.13M | $25.20M | -3.56% | -$0.84 | -$0.55 | +34.52% | — | — |
| Q3 2024 Aug 13, 2024 | $23.96M | $21.85M | -8.81% | -$0.82 | -$0.91 | -10.98% | — | — |
| Q2 2024 May 13, 2024 | $21.38M | $18.78M | -12.16% | -$0.93 | -$0.97 | -4.30% | — | — |
| Q1 2024 Mar 14, 2024 | $22.57M | $23.53M | +4.25% | -$0.67 | -$0.72 | -7.46% | — | — |
| Q4 2023 Nov 14, 2023 | $22.57M | $20.85M | -7.61% | -$0.89 | -$0.68 | +23.60% | — | — |
| Q3 2023 Aug 10, 2023 | $20.12M | $21.14M | +5.06% | -$1.13 | -$1.03 | +8.85% | — | — |
| Q2 2023 May 11, 2023 | $17.18M | $17.19M | +0.07% | -$1.39 | -$1.30 | +6.47% | — | — |
| Q1 2023 Mar 16, 2023 | $18.51M | $18.09M | -2.26% | -$1.12 | -$1.22 | -8.93% | — | — |
| Q4 2022 Nov 10, 2022 | $20.15M | $16.10M | -20.10% | -$1.22 | -$1.13 | +7.38% | — | — |
| Q3 2022 Aug 11, 2022 | $17.22M | $16.60M | -3.60% | -$1.33 | -$1.18 | +11.28% | — | — |
| Q2 2022 May 10, 2022 | $15.17M | $13.56M | -10.60% | -$1.36 | -$1.25 | +8.09% | — | — |
| Q1 2022 Mar 21, 2022 | $16.24M | $16.17M | -0.43% | -$1.18 | -$1.27 | -7.63% | — | — |
| Q4 2021 Nov 15, 2021 | $15.42M | $11.35M | -26.39% | -$1.26 | -$1.35 | -7.14% | — | — |
| Q3 2021 Aug 4, 2021 | $13.03M | $13.03M | +0.00% | -$1.10 | -$1.17 | -6.36% | — | — |
| Q2 2021 May 13, 2021 | $9.00M | $7.49M | -16.83% | -$1.26 | -$1.17 | +7.14% | — | — |